A J Vaught1, T Ozrazgat-Baslanti1, A Javed1, L Morgan2, C E Hobson3,4, A Bihorac1. 1. Department of Anesthesiology, University of Florida, Gainesville, FL, USA. 2. Department of Gynecology, University of Florida, Gainesville, FL, USA. 3. Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, USA. 4. Department of Surgery, Malcom Randall Veterans Affairs Medical Center, Gainesville, FL, USA.
Abstract
OBJECTIVE: To assess the prevalence, outcomes and cost associated with acute kidney injury (AKI) defined by consensus risk, injury, failure, loss, and end-stage kidney (RIFLE) criteria after gynaecologic surgery. DESIGN: Retrospective single-centre cohort study. SETTING: Academic medical centre. SAMPLE: Two thousand three hundred and forty-one adult women undergoing major inpatient gynaecologic surgery between January 2000 and November 2010. METHODS: AKI was defined by RIFLE criteria as an increase in serum creatinine greater than or equal to 50% from the reference creatinine. We used multivariable regression analyses to determine the association between perioperative factors, AKI, mortality and cost. MAIN OUTCOME MEASURES: AKI, combined major adverse events (hospital mortality, sepsis or mechanical ventilation), 90-day mortality and hospital cost. RESULTS: Overall prevalence of AKI was 13%. The prevalence of AKI was associated with the primary diagnosis. Of women with benign tumour surgeries, 5% (43/801) experienced AKI compared with 18% (211/1159) of women with malignant disease (P < 0.001). Only 1.3% of the whole cohort had evidence of urologic mechanical injury. In a multivariable logistic regression analysis, AKI patients had nine times the odds of a major adverse event compared to patients without AKI (adjusted odds ratio 8.95, 95% confidence interval 5.27-15.22). We have identified several readily available perioperative factors that can be used to identify patients at high risk for AKI after in-hospital gynaecologic surgery. CONCLUSIONS: AKI is a common complication after major inpatient gynaecologic surgery associated with an increase in resource utilisation and hospital cost, morbidity and mortality.
OBJECTIVE: To assess the prevalence, outcomes and cost associated with acute kidney injury (AKI) defined by consensus risk, injury, failure, loss, and end-stage kidney (RIFLE) criteria after gynaecologic surgery. DESIGN: Retrospective single-centre cohort study. SETTING: Academic medical centre. SAMPLE: Two thousand three hundred and forty-one adult women undergoing major inpatient gynaecologic surgery between January 2000 and November 2010. METHODS: AKI was defined by RIFLE criteria as an increase in serum creatinine greater than or equal to 50% from the reference creatinine. We used multivariable regression analyses to determine the association between perioperative factors, AKI, mortality and cost. MAIN OUTCOME MEASURES: AKI, combined major adverse events (hospital mortality, sepsis or mechanical ventilation), 90-day mortality and hospital cost. RESULTS: Overall prevalence of AKI was 13%. The prevalence of AKI was associated with the primary diagnosis. Of women with benign tumour surgeries, 5% (43/801) experienced AKI compared with 18% (211/1159) of women with malignant disease (P < 0.001). Only 1.3% of the whole cohort had evidence of urologic mechanical injury. In a multivariable logistic regression analysis, AKI patients had nine times the odds of a major adverse event compared to patients without AKI (adjusted odds ratio 8.95, 95% confidence interval 5.27-15.22). We have identified several readily available perioperative factors that can be used to identify patients at high risk for AKI after in-hospital gynaecologic surgery. CONCLUSIONS: AKI is a common complication after major inpatient gynaecologic surgery associated with an increase in resource utilisation and hospital cost, morbidity and mortality.
Authors: Damien J LaPar; Castigliano M Bhamidipati; Carlos M Mery; George J Stukenborg; David R Jones; Bruce D Schirmer; Irving L Kron; Gorav Ailawadi Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Edward D Siew; T Alp Ikizler; Michael E Matheny; Yaping Shi; Jonathan S Schildcrout; Ioana Danciu; Jamie P Dwyer; Manakan Srichai; Adriana M Hung; James P Smith; Josh F Peterson Journal: Clin J Am Soc Nephrol Date: 2012-03-15 Impact factor: 8.237
Authors: Azra Bihorac; Matthew J Delano; Jesse D Schold; Maria Cecilia Lopez; Avery B Nathens; Ronald V Maier; Abraham Joseph Layon; Henry V Baker; Lyle L Moldawer Journal: Ann Surg Date: 2010-07 Impact factor: 12.969
Authors: Azra Bihorac; Meghan Brennan; Tezcan Ozrazgat-Baslanti; Shahab Bozorgmehri; Philip A Efron; Frederick A Moore; Mark S Segal; Charles E Hobson Journal: Crit Care Med Date: 2013-11 Impact factor: 7.598
Authors: Matthew Huber; Tezcan Ozrazgat-Baslanti; Paul Thottakkara; Philip A Efron; Robert Feezor; Charles Hobson; Azra Bihorac Journal: Ann Vasc Surg Date: 2015-07-14 Impact factor: 1.466
Authors: Tezcan Ozrazgat-Baslanti; Paulette Blanc; Paul Thottakkara; Matthew Ruppert; Parisa Rashidi; Petar Momcilovic; Charles Hobson; Philip A Efron; Frederick A Moore; Azra Bihorac Journal: Surgery Date: 2016-05-26 Impact factor: 3.982
Authors: Sarah P Huepenbecker; Maria D Iniesta; Andrés Zorrilla-Vaca; Pedro T Ramirez; Katherine E Cain; Micah Vaughn; Juan P Cata; Gabriel E Mena; Javier Lasala; Larissa A Meyer Journal: Gynecol Oncol Date: 2021-08-13 Impact factor: 5.304
Authors: Adam Lewis; Lisa Bastarache; Anita Pandit; Daniel B Larach; Jing He; Anik Sinha; Nicholas J Douville; Michael Heung; Michael R Mathis; Jonathan D Mosley; Jonathan P Wanderer; Sachin Kheterpal; Matthew Zawistowski; Chad M Brummett; Edward D Siew; Cassianne Robinson-Cohen; Miklos D Kertai Journal: BMC Nephrol Date: 2022-10-21 Impact factor: 2.585